1. Home
  2. STOK vs AHH Comparison

STOK vs AHH Comparison

Compare STOK & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • AHH
  • Stock Information
  • Founded
  • STOK 2014
  • AHH 1979
  • Country
  • STOK United States
  • AHH United States
  • Employees
  • STOK N/A
  • AHH N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • AHH Real Estate
  • Sector
  • STOK Health Care
  • AHH Finance
  • Exchange
  • STOK Nasdaq
  • AHH Nasdaq
  • Market Cap
  • STOK 517.0M
  • AHH 586.7M
  • IPO Year
  • STOK 2019
  • AHH 2013
  • Fundamental
  • Price
  • STOK $9.87
  • AHH $7.00
  • Analyst Decision
  • STOK Strong Buy
  • AHH Buy
  • Analyst Count
  • STOK 5
  • AHH 3
  • Target Price
  • STOK $24.50
  • AHH $9.83
  • AVG Volume (30 Days)
  • STOK 694.7K
  • AHH 917.0K
  • Earning Date
  • STOK 05-13-2025
  • AHH 05-07-2025
  • Dividend Yield
  • STOK N/A
  • AHH 10.85%
  • EPS Growth
  • STOK N/A
  • AHH 9.49
  • EPS
  • STOK 0.88
  • AHH 0.10
  • Revenue
  • STOK $190,908,000.00
  • AHH $627,963,000.00
  • Revenue This Year
  • STOK $44.17
  • AHH N/A
  • Revenue Next Year
  • STOK $20.00
  • AHH $2.00
  • P/E Ratio
  • STOK $10.88
  • AHH $72.14
  • Revenue Growth
  • STOK 2333.81
  • AHH N/A
  • 52 Week Low
  • STOK $5.35
  • AHH $6.10
  • 52 Week High
  • STOK $17.58
  • AHH $12.46
  • Technical
  • Relative Strength Index (RSI)
  • STOK 55.15
  • AHH 45.64
  • Support Level
  • STOK $9.09
  • AHH $6.88
  • Resistance Level
  • STOK $9.83
  • AHH $7.20
  • Average True Range (ATR)
  • STOK 0.61
  • AHH 0.18
  • MACD
  • STOK -0.05
  • AHH -0.01
  • Stochastic Oscillator
  • STOK 51.93
  • AHH 28.26

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: